Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HDACi Delivery Reprograms Tumor-Infiltrating Myeloid Cells to Eliminate Antigen-Loss Variants.

Cell reports - 17 Jul 2018

Nguyen Andrew, Ho Louisa, Workenhe Samuel T, Chen Lan, Samson Jonathan, Walsh Scott R, Pol Jonathan, Bramson Jonathan L, Wan Yonghong

Abstract excerpt

Immune recognition of tumor-expressed antigens by cytotoxic CD8+ T cells is the foundation of adoptive T cell therapy (ACT) and has been shown to elicit significant tumor regression. However, therapy-induced selective pressure can sculpt the antigenicity of tumors, resulting in outgrowth of variants that lose the target antigen. We demonstrate that tumor relapse from ACT and subsequent oncolytic viral vaccination...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cellular Reprogramming
Share to Histone Deacetylase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunity

Share to Immunotherapy, Adoptive

Share to Interferon gamma Receptor

Share to Melanoma, Experimental

Share to Myeloid Cells

Share to Receptors, Interferon

Source

Identifiers

PMID: 30021162
DOI: 10.1016/j.celrep.2018.06.040

Genes

NOS2
STAT1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HDACi Delivery Reprograms Tumor-Infiltrating Myeloid Cells to Eliminate Antigen-Loss Variants.PMID 30021162Read ↗

Therapeutic Blockade of Type 2 Cytokines and PD1 Unleashes Anti-Tumor Immunity Through Coordinated Reprogramming of Innate and Adaptive Immune SurveillanceSemantic proximity Read ↗

Macrophage Antigen Presentation Is Unleashed by Pan-RAS Inhibition to Promote Antitumor ImmunitySemantic proximity Read ↗

SUMO2 Deletion Changes Chromatin Accessibility and Enhances Cytotoxic T Cell Activation and Tumor InfiltrationSemantic proximity Read ↗

Spatiotemporal dynamics of adoptively transferred stem-like CD8 <sup>+</sup> T cells in the tumor microenvironment following vaccinationSemantic proximity Read ↗

Reprogramming Cancer into Antigen-Presenting Cells as a Novel ImmunotherapySemantic proximity Read ↗

Epigenetic remodeling via HDAC6 inhibition amplifies anti-tumoral immune responses in myeloid leukemia cellsSemantic proximity Read ↗

Advances of HDAC inhibitors in tumor therapy: potential applications through immune modulationSemantic proximity Read ↗

CD4+ T cell-induced inflammatory killing controls immune evasive tumoursSemantic proximity Read ↗

The immunomodulatory properties of the HDAC6 inhibitor ACY241 supports robust anti-tumor response in NSCLC when coupled with the chemotherapy drug OxaliplatinSemantic proximity Read ↗

Interferon gene therapy reprograms the leukemia microenvironment inducing protective immunity to multiple tumor antigensSemantic proximity Read ↗

Overcoming immune evasion from post-translational modification of a mutant KRAS epitope to achieve TCR-T cell-mediated antitumor activitySemantic proximity Read ↗

Histone Deacetylase Inhibitors as Immunomodulators in Cancer TherapeuticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.